Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
United Kingdom (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      CD38 (HB7) BV605
      Product Details
      Down Arrow Up Arrow


      BD®
      Human
      Mouse IgG1, κ
      Human BJAB B cell line
      5 µl
      III B918
      CE_IVD


      Preparation And Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions and unconjugated antibody and free dye were removed.

      The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
      2. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
      Show More blue down arrow Show Less blue up arrow
      664451 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      HB7
      664451 Rev. 1
      Format Details
      Down Arrow Up Arrow
      BV605
      The BD Horizon Brilliant Violet™ 605 (BV605) dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 605-nm. BV605, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 610-nm (e.g., a 610/20-nm bandpass filter). The acceptor dye can be excited by the yellow-green (561-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BV605
      Violet 405 nm
      407 nm
      605 nm
      664451 Rev.1
      Citations & References
      Down Arrow Up Arrow
      View product citations for antibody "664451" on CiteAb

      Development References (20)

      1. Anastasiadis A, Kotsianidis I, Papadopoulos V, et al. CD1d expression as a prognostic marker for chronic lymphocytic leukemia.. Leuk Lymphoma. 2014; 55(2):320-5. View Reference
      2. Clinical and Laboratory Standards Institute. Collection of Diagnostic Venous Blood Specimens, 7th ed. In: CLSI. CLSI, ed. CLSI document GP41-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2017:1-85. View Reference
      3. Courville EL, Yohe S, Shivers P, Linden MA. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.. Am J Clin Pathol. 2020; 153(2):221-228. View Reference
      4. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol. 1998; 160(1):395-402. View Reference
      5. Dörken B, Möller P, Pezzutto A, Schwartz-Albiez R, Moldenhauer G. B-cell antigens: CD38. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:86.
      6. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood. 2003; 101(4):1262-1269. View Reference
      7. Giorgi J, Hultin L. Lymphocyte subset alterations and immunophenotyping by flow cytometry in HIV disease. Clin Immunol Newslett. 1990; 10(4):55-61.
      8. Landay A, Ohlsson-Wilhelm B, Giorgi JV. Application of flow cytometry to the study of HIV infection. AIDS. 1990; 4(6):479-497. View Reference
      9. Nicholson JKA, Jones BM. Immunophenotyping by flow cytometry: its use in HIV infection. Labmedica. 1989; 6:21-26.
      10. Perbellini O, Falisi E, Giaretta I, et al. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.. Haematologica. 2014; 99(5):881-7. View Reference
      11. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis.. Leukemia. 1996; 10(5):877-95. View Reference
      12. Salazar-Gonzalez JF, Moody DJ, Giorgi JV, Martinez-Maza O, Mitsuyasu RT, Fahey JL. Reduced ecto-5'-nucleotidase activity and enhanced OKT10 and HLA-DR expression on CD8 (T suppressor/cytotoxic) lymphocytes in the acquired immune deficiency syndrome: evidence of CD8 cell immaturity. J Immunol. 1985; 135(3):1778-1785. View Reference
      13. Sargent RL, Craig FE, Swerdlow SH. Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.. Int J Clin Exp Pathol. 2009; 2(6):574-82. View Reference
      14. Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.. Am J Clin Pathol. 2009; 132(6):940-9. View Reference
      15. Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230.
      16. Tedder TF, Clement LT, Cooper MD. Discontinuous expression of a membrane antigen (HB-7) during B lymphocyte differentiation. Tissue Antigens. 1984; 24(3):140-149. View Reference
      17. Tedder TF, Crain MJ, Kubagawa H, Clement LT, Cooper MD. Evaluation of lymphocyte differentiation in primary and secondary immunodeficiency diseases. J Immunol. 1985; 135(3):1785-1791. View Reference
      18. Terstappen LW, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990; 48(2):138-148. View Reference
      19. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood. 1991; 77(6):1218-1227. View Reference
      20. Terstappen LWMM, Huang S, Picker LJ. Flow cytometric assessment of human T-cell differentiation inthymus and bone marrow. Blood. 1992; 79:666-677.
      View All (20) View Less
      664451 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.

      Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.